Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Differences Between Patients Enrolled Early and Late During Clinical Trial Recruitment: Insights From the HF-ACTION Trial.

Warraich HJ, O'Connor C, Wu A, Coles A, Kraus WE, Piña IL, Whellan DJ, Mentz RJ.

Circ Cardiovasc Qual Outcomes. 2018 Jul;11(7):e004643. doi: 10.1161/CIRCOUTCOMES.117.004643. No abstract available.

PMID:
29980656
2.

Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1).

Lennox BR, Tomei G, Vincent SA, Yeeles K, Pollard R, Palmer-Cooper E, Jones P, Zandi MS, Coles A.

J Neurol Neurosurg Psychiatry. 2018 Jun 11. pii: jnnp-2018-318124. doi: 10.1136/jnnp-2018-318124. [Epub ahead of print] No abstract available.

PMID:
29891740
3.

Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features.

Pariani N, Willis M, Muller I, Healy S, Nasser T, McGowan A, Lyons G, Jones J, Chatterjee K, Dayan C, Robertson N, Coles A, Moran C.

J Clin Endocrinol Metab. 2018 Jun 6. doi: 10.1210/jc.2018-00359. [Epub ahead of print]

PMID:
29878256
4.

Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs.

Osborn MF, Coles AH, Golebiowski D, Echeverria D, Moazami MP, Watts JK, Sena-Esteves M, Khvorova A.

Mol Cancer Ther. 2018 Jun;17(6):1251-1258. doi: 10.1158/1535-7163.MCT-17-1144. Epub 2018 Apr 13.

PMID:
29654062
5.

Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.

Saarela M, Senthil K, Jones J, Tienari PJ, Soilu-Hänninen M, Airas L, Coles A, Saarinen JT.

Neurology. 2018 May 1;90(18):849-851. doi: 10.1212/WNL.0000000000005420. Epub 2018 Mar 30. No abstract available.

PMID:
29602914
6.

Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from 23Na-MRI.

Grist JT, Riemer F, McLean MA, Matys T, Zaccagna F, Hilborne SF, Mason JP, Patterson I, Slough R, Kaggie J, Deen SS, Graves MJ, Jones JL, Coles AJ, Gallagher FA.

J Neurol Sci. 2018 Apr 15;387:111-114. doi: 10.1016/j.jns.2018.01.027. Epub 2018 Feb 6.

7.

High-Sensitivity Troponin I and Coronary Computed Tomography in Symptomatic Outpatients With Suspected Coronary Artery Disease: Insights From the PROMISE Trial.

Januzzi JL Jr, Suchindran S, Coles A, Ferencik M, Patel MR, Hoffmann U, Ginsburg GS, Douglas PS; PROMISE Investigators.

JACC Cardiovasc Imaging. 2018 Mar 9. pii: S1936-878X(18)30132-3. doi: 10.1016/j.jcmg.2018.01.021. [Epub ahead of print]

PMID:
29550314
8.

Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial.

Cerbin LP, Ambrosy AP, Greene SJ, Armstrong PW, Butler J, Coles A, DeVore AD, Ezekowitz JA, Hernandez AF, Metra M, Starling RC, Tang W, Teerlink JR, Voors AA, Wu A, O'Connor CM, Mentz RJ.

JACC Heart Fail. 2018 Apr;6(4):298-307. doi: 10.1016/j.jchf.2018.01.018. Epub 2018 Mar 7.

PMID:
29525328
9.

Authorship of phase 3 trials in multiple sclerosis.

Coles A.

Ann Neurol. 2018 Apr;83(4):653-655. doi: 10.1002/ana.25203. No abstract available.

PMID:
29518276
10.

Alemtuzumab as Treatment for Multiple Sclerosis.

Katsavos S, Coles A.

Cold Spring Harb Perspect Med. 2018 Mar 2. pii: a032029. doi: 10.1101/cshperspect.a032029. [Epub ahead of print]

PMID:
29500306
11.

A review of brain stimulation methods to treat substance use disorders.

Coles AS, Kozak K, George TP.

Am J Addict. 2018 Mar;27(2):71-91. doi: 10.1111/ajad.12674. Epub 2018 Feb 19. Review.

12.

Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo.

Hassler MR, Turanov AA, Alterman JF, Haraszti RA, Coles AH, Osborn MF, Echeverria D, Nikan M, Salomon WE, Roux L, Godinho BMDC, Davis SM, Morrissey DV, Zamore PD, Karumanchi SA, Moore MJ, Aronin N, Khvorova A.

Nucleic Acids Res. 2018 Mar 16;46(5):2185-2196. doi: 10.1093/nar/gky037.

13.

Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

Bhatt AS, Cooper LB, Ambrosy AP, Clare RM, Coles A, Joyce E, Krishnamoorthy A, Butler J, Felker GM, Ezekowitz JA, Armstrong PW, Hernandez AF, O'Connor CM, Mentz RJ.

J Am Heart Assoc. 2018 Feb 3;7(3). pii: e006740. doi: 10.1161/JAHA.117.006740.

14.

Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells.

Smets I, Fiddes B, Garcia-Perez JE, He D, Mallants K, Liao W, Dooley J, Wang G, Humblet-Baron S, Dubois B, Compston A, Jones J, Coles A, Liston A, Ban M, Goris A, Sawcer S.

Brain. 2018 Jan 18. doi: 10.1093/brain/awx372. [Epub ahead of print]

15.

Impact of Diabetes Mellitus on the Evaluation of Stable Chest Pain Patients: Insights From the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) Trial.

Sharma A, Sekaran NK, Coles A, Pagidipati NJ, Hoffmann U, Mark DB, Lee KL, Al-Khalidi HR, Lu MT, Pellikka PA, Trong QA, Douglas PS.

J Am Heart Assoc. 2017 Oct 31;6(11). pii: e007019. doi: 10.1161/JAHA.117.007019.

16.

Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF.

Fudim M, O'Connor CM, Dunning A, Ambrosy AP, Armstrong PW, Coles A, Ezekowitz JA, Greene SJ, Metra M, Starling RC, Voors AA, Hernandez AF, Michael Felker G, Mentz RJ.

Eur J Heart Fail. 2018 Feb;20(2):304-314. doi: 10.1002/ejhf.1020. Epub 2017 Oct 29.

PMID:
29082629
17.

Pharmacokinetic Profiling of Conjugated Therapeutic Oligonucleotides: A High-Throughput Method Based Upon Serial Blood Microsampling Coupled to Peptide Nucleic Acid Hybridization Assay.

Godinho BMDC, Gilbert JW, Haraszti RA, Coles AH, Biscans A, Roux L, Nikan M, Echeverria D, Hassler M, Khvorova A.

Nucleic Acid Ther. 2017 Dec;27(6):323-334. doi: 10.1089/nat.2017.0690. Epub 2017 Oct 12.

PMID:
29022758
18.

A High-throughput Assay for mRNA Silencing in Primary Cortical Neurons in vitro with Oligonucleotide Therapeutics.

Alterman JF, Coles AH, Hall LM, Aronin N, Khvorova A, Didiot MC.

Bio Protoc. 2017 Aug 20;7(16). pii: e2501. doi: 10.21769/BioProtoc.2501.

19.

Quantifying sociodemographic and income disparities in medical therapy and lifestyle among symptomatic patients with suspected coronary artery disease: a cross-sectional study in North America.

Ladapo JA, Coles A, Dolor RJ, Mark DB, Cooper L, Lee KL, Goldberg J, Shapiro MD, Hoffmann U, Douglas PS.

BMJ Open. 2017 Sep 29;7(9):e016364. doi: 10.1136/bmjopen-2017-016364.

20.

A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers.

Mori AM, Agarwal S, Lee MWM, Rafferty M, Hardy TA, Coles A, Reddel SW, Riminton DS.

J Neuroimmunol. 2017 Nov 15;312:4-7. doi: 10.1016/j.jneuroim.2017.08.009. Epub 2017 Aug 24.

PMID:
28886954
21.

Loading of Extracellular Vesicles with Chemically Stabilized Hydrophobic siRNAs for the Treatment of Disease in the Central Nervous System.

Haraszti RA, Coles A, Aronin N, Khvorova A, Didiot MC.

Bio Protoc. 2017 Jun 20;7(20). pii: e2338. doi: 10.21769/BioProtoc.2338.

22.

Physician-assisted death should be available to people with MS - Commentary.

Coles A.

Mult Scler. 2017 Nov;23(13):1681. doi: 10.1177/1352458517730133. Epub 2017 Sep 1. No abstract available.

PMID:
28859536
23.

Prognostic Value of Coronary Artery Calcium in the PROMISE Study (Prospective Multicenter Imaging Study for Evaluation of Chest Pain).

Budoff MJ, Mayrhofer T, Ferencik M, Bittner D, Lee KL, Lu MT, Coles A, Jang J, Krishnam M, Douglas PS, Hoffmann U; PROMISE Investigators.

Circulation. 2017 Nov 21;136(21):1993-2005. doi: 10.1161/CIRCULATIONAHA.117.030578. Epub 2017 Aug 28.

PMID:
28847895
24.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

25.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

26.

Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2.

Pekalski ML, García AR, Ferreira RC, Rainbow DB, Smyth DJ, Mashar M, Brady J, Savinykh N, Dopico XC, Mahmood S, Duley S, Stevens HE, Walker NM, Cutler AJ, Waldron-Lynch F, Dunger DB, Shannon-Lowe C, Coles AJ, Jones JL, Wallace C, Todd JA, Wicker LS.

JCI Insight. 2017 Aug 17;2(16). pii: 93739. doi: 10.1172/jci.insight.93739. [Epub ahead of print]

27.

Hypothyroid ataxia complicating monoclonal antibody therapy.

Badran A, Moran C, Coles AJ.

Pract Neurol. 2017 Dec;17(6):482-484. doi: 10.1136/practneurol-2017-001713. Epub 2017 Aug 4.

PMID:
28778931
28.

Use of Polycaprolactone Electrospun Nanofibers as a Coating for Poly(methyl methacrylate) Bone Cement.

Khandaker M, Riahinezhad S, Jamadagni HG, Morris TL, Coles AV, Vaughan MB.

Nanomaterials (Basel). 2017 Jul 10;7(7). pii: E175. doi: 10.3390/nano7070175.

29.

Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial.

Greene SJ, Hernandez AF, Dunning A, Ambrosy AP, Armstrong PW, Butler J, Cerbin LP, Coles A, Ezekowitz JA, Metra M, Starling RC, Teerlink JR, Voors AA, O'Connor CM, Mentz RJ.

J Am Coll Cardiol. 2017 Jun 27;69(25):3029-3039. doi: 10.1016/j.jacc.2017.04.043.

30.

The External Validity of Prediction Models for the Diagnosis of Obstructive Coronary Artery Disease in Patients With Stable Chest Pain: Insights From the PROMISE Trial.

Genders TSS, Coles A, Hoffmann U, Patel MR, Mark DB, Lee KL, Steyerberg EW, Hunink MGM, Douglas PS; CAD Consortium and the PROMISE Investigators.

JACC Cardiovasc Imaging. 2018 Mar;11(3):437-446. doi: 10.1016/j.jcmg.2017.02.020. Epub 2017 Jun 14.

PMID:
28624401
31.

5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo.

Haraszti RA, Roux L, Coles AH, Turanov AA, Alterman JF, Echeverria D, Godinho BMDC, Aronin N, Khvorova A.

Nucleic Acids Res. 2017 Jul 27;45(13):7581-7592. doi: 10.1093/nar/gkx507.

32.

Synthesis and Evaluation of Parenchymal Retention and Efficacy of a Metabolically Stable O-Phosphocholine-N-docosahexaenoyl-l-serine siRNA Conjugate in Mouse Brain.

Nikan M, Osborn MF, Coles AH, Biscans A, Godinho BMDC, Haraszti RA, Sapp E, Echeverria D, DiFiglia M, Aronin N, Khvorova A.

Bioconjug Chem. 2017 Jun 21;28(6):1758-1766. doi: 10.1021/acs.bioconjchem.7b00226. Epub 2017 May 10.

33.

An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial.

Voora D, Coles A, Lee KL, Hoffmann U, Wingrove JA, Rhees B, Huang L, Daniels SE, Monane M, Rosenberg S, Shah SH, Kraus WE, Ginsburg GS, Douglas PS.

Am Heart J. 2017 Feb;184:133-140. doi: 10.1016/j.ahj.2016.11.004. Epub 2016 Nov 15.

34.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group.

Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.

PMID:
28209331
35.

Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.

Barton J, Hardy TA, Riminton S, Reddel SW, Barnett Y, Coles A, Barnett MH.

Neurology. 2017 Mar 7;88(10):1004-1006. doi: 10.1212/WNL.0000000000003694. Epub 2017 Feb 8. No abstract available.

PMID:
28179462
36.

Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial.

Ambrosy AP, Cerbin LP, Armstrong PW, Butler J, Coles A, DeVore AD, Dunlap ME, Ezekowitz JA, Felker GM, Fudim M, Greene SJ, Hernandez AF, O'Connor CM, Schulte P, Starling RC, Teerlink JR, Voors AA, Mentz RJ.

JACC Heart Fail. 2017 Jan;5(1):1-13. doi: 10.1016/j.jchf.2016.09.012.

37.

Progressive multifocal leucoencephalopathy with Behçet's disease: an insight into pathophysiology.

Agarwal S, Patrick J, Jones J, Smith R, Coles A, Jayne D.

Rheumatology (Oxford). 2017 Apr 1;56(4):668-670. doi: 10.1093/rheumatology/kew404. No abstract available.

PMID:
28013192
38.

A novel electromechanical autoinjector, AutoTouch™, for self-injection of etanercept: real-world use and benefits.

Collier DH, Bitman B, Coles A, Liu L, Kumar S, Judd C.

Postgrad Med. 2017 Jan;129(1):118-125. doi: 10.1080/00325481.2017.1251291. Epub 2016 Nov 9.

PMID:
27829325
39.

Does empathy predict altruism in the wild?

Bethlehem RAI, Allison C, van Andel EM, Coles AI, Neil K, Baron-Cohen S.

Soc Neurosci. 2017 Dec;12(6):743-750. doi: 10.1080/17470919.2016.1249944. Epub 2016 Oct 28.

PMID:
27759496
40.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

41.

Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease.

Ladapo JA, Hoffmann U, Lee KL, Coles A, Huang M, Mark DB, Dolor RJ, Pelberg RA, Budoff M, Sigurdsson G, Severance HW, Douglas PS.

J Am Heart Assoc. 2016 Oct 12;5(10). pii: e003807.

42.

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH, Thomas DR, Panzara MA, Compston DA; CARE-MS I and CARE-MS II Investigators.

Neurology. 2016 Oct 4;87(14):1464-1472. Epub 2016 Sep 2.

43.

Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION).

Parikh KS, Coles A, Schulte PJ, Kraus WE, Fleg JL, Keteyian SJ, Piña IL, Fiuzat M, Whellan DJ, O'Connor CM, Mentz RJ.

Am J Cardiol. 2016 Oct 15;118(8):1211-1216. doi: 10.1016/j.amjcard.2016.07.040. Epub 2016 Jul 29.

44.

Exosome-mediated Delivery of Hydrophobically Modified siRNA for Huntingtin mRNA Silencing.

Didiot MC, Hall LM, Coles AH, Haraszti RA, Godinho BM, Chase K, Sapp E, Ly S, Alterman JF, Hassler MR, Echeverria D, Raj L, Morrissey DV, DiFiglia M, Aronin N, Khvorova A.

Mol Ther. 2016 Oct;24(10):1836-1847. doi: 10.1038/mt.2016.126. Epub 2016 Jun 27.

45.

Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain.

Nikan M, Osborn MF, Coles AH, Godinho BM, Hall LM, Haraszti RA, Hassler MR, Echeverria D, Aronin N, Khvorova A.

Mol Ther Nucleic Acids. 2016 Aug 9;5(8):e344. doi: 10.1038/mtna.2016.50.

46.

Increased THEMIS First Exon Usage in CD4+ T-Cells Is Associated with a Genotype that Is Protective against Multiple Sclerosis.

Davies JL, Thompson S, Kaur-Sandhu H, Sawcer S, Coles A, Ban M, Jones J.

PLoS One. 2016 Jul 20;11(7):e0158327. doi: 10.1371/journal.pone.0158327. eCollection 2016.

47.

A Case of Complex PFO Leading to Ischemic Stroke: A Practical Clinical Pearl for Neurohospitalists.

Coles A, Haveman-Gould B, Farooq MU, Selke KJ, Gorelick PB.

Neurohospitalist. 2016 Jul;6(3):114-7. doi: 10.1177/1941874415588750. Epub 2015 Jun 2.

48.

Sex Differences in Functional and CT Angiography Testing in Patients With Suspected Coronary Artery Disease.

Pagidipati NJ, Hemal K, Coles A, Mark DB, Dolor RJ, Pellikka PA, Hoffmann U, Litwin SE, Udelson J, Daubert MA, Shah SH, Martinez B, Lee KL, Douglas PS.

J Am Coll Cardiol. 2016 Jun 7;67(22):2607-16. doi: 10.1016/j.jacc.2016.03.523. Epub 2016 Apr 4.

49.

Sex Differences in Demographics, Risk Factors, Presentation, and Noninvasive Testing in Stable Outpatients With Suspected Coronary Artery Disease: Insights From the PROMISE Trial.

Hemal K, Pagidipati NJ, Coles A, Dolor RJ, Mark DB, Pellikka PA, Hoffmann U, Litwin SE, Daubert MA, Shah SH, Ariani K, Bullock-Palmer RP, Martinez B, Lee KL, Douglas PS.

JACC Cardiovasc Imaging. 2016 Apr;9(4):337-46.

50.

Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.

Fox EJ, Wynn D, Coles AJ, Palmer J, Margolin DH; CAMMS223 Investigators.

J Neurol Sci. 2016 Apr 15;363:188-94. doi: 10.1016/j.jns.2016.02.025. Epub 2016 Feb 12.

Supplemental Content

Support Center